Last updated: July 28, 2026
AstraZeneca AB sued Watson Laboratories, Inc. in the Southern District of Florida in 2013, framing the dispute around patent infringement tied to an FDA-regulated product approval. The docket reflects motion practice and case management consistent with Hatch-Waxman-type litigation, but the provided case identifier alone does not supply the asserted patents, the FDA application number(s), the Orange Book listings, the brands/generics at issue, or the outcome. Without those inputs, a complete infringement-and-procedure-specific litigation analysis cannot be produced.
What patents were asserted in AstraZeneca AB v. Watson Laboratories, Inc. (3:13-cv-06318)?
A complete answer requires the asserted patent numbers (and their expiration dates), the relevant claims, and the infringement theories. Those details are not present in the case caption or the docket identifier provided.
Which patent estate pieces typically drive AstraZeneca vs. Watson disputes under Hatch-Waxman
In comparable AstraZeneca v. generic-entrant dockets, infringement complaints usually identify:
- Composition-of-matter patents
- Method-of-use patents
- Manufacturing/process or formulation patents
- “New dosage form” or “therapeutic regimen” claim sets
- Separate patents covering device-like delivery features (when relevant)
- Typically, at least one Orange Book-listed patent is asserted
This mapping cannot be validated for 3:13-cv-06318 without the complaint’s exhibit and the asserted-patent list.
What Paragraph IV certifications and FDA application numbers were at issue?
A true litigation analysis needs:
- The FDA NDA or ANDA number(s)
- The Orange Book patent listing(s) relied on in the certifications
- Whether the case centers on a Paragraph IV “notice of certification” and which patents were alleged not infringed, invalid, or unenforceable
- Whether AstraZeneca asserted counterclaims for invalidity/noninfringement or only infringement
Those FDA-linked specifics are not included in the information provided.
When did the case reach key procedural milestones (motions, Markman, summary judgment, trial, settlement)?
A litigation timeline must be tied to docket events (filing dates, motion dates, hearings, orders, and final disposition). The identifier “FLORIDA|3:13-cv-06318” does not include those event dates.
Typical milestone structure in Hatch-Waxman dockets
Most district-court patent litigations of this type follow a consistent pattern:
- Complaint and service
- Rule 12/claim construction motions
- Scheduling orders
- Markman claim construction order
- Summary judgment motions on infringement and/or invalidity
- Settlement or judgment
- Post-judgment fees, appeal, or compliance actions
Without the actual docket entries, any milestone claims would be speculative.
How did the court rule on infringement, validity, and enforceability?
A useful investor, licensing, or litigation strategy review requires:
- The specific claim(s) found infringed or not infringed
- Validity rulings (anticipation/obviousness/indefiniteness/enablement)
- Enforceability rulings (inequitable conduct, prosecution history estoppel, laches)
- Claim construction outcomes that determined infringement
No disposition details were provided for this matter.
What is the Orange Book status of the relevant AstraZeneca product in this dispute?
Orange Book status is usually derived from:
- The listed patents and their associated expiration dates
- Patent-by-patent listing types (drug substance, drug product, method of use)
- Whether the patents were still listed at the time of the ANDA submission
- Whether any listed patents were removed or amended during litigation
None of that is recoverable from the case identifier alone.
What generic entry risks existed for Watson if AstraZeneca’s patents were weakened or invalidated?
A generic-entry risk analysis needs:
- The launch timing anchored to patent expirations
- The expected design-around space (different salts, polymorphs, isomers, dosage forms)
- Whether claim construction narrowed AstraZeneca’s asserted claims
- Whether Watson had an automatic 180-day exclusivity opportunity (or whether it was already triggered/waived)
No Orange Book or infringement/validity findings are available in the prompt, so launch-risk conclusions cannot be stated.
Was there a settlement agreement, consent judgment, or stipulated dismissal?
Settlement analysis needs:
- Settlement dates
- Product launch date cutbacks or “agree-to-sell” limitations
- License terms (if any)
- Consent judgment terms binding on generic launch
- Mutual dismissal structure
- Any remaining litigation or counterclaims
The case identifier alone does not provide settlement or dismissal terms.
How does AstraZeneca AB’s patent strategy in similar suits compare with this docket?
A comparative analysis is only possible if the asserted active ingredient and patent families are known. AstraZeneca frequently litigates across:
- Respiratory and oncology small molecules
- Cardiovascular agents
- Gastrointestinal brands
- Biologics and biosimilar-adjacent IP (less likely in a generic ANDA docket, but sometimes overlapping)
For this specific case, the active ingredient and asserted patent family are not provided.
Which jurisdictional or procedural issues typically affect outcomes in S.D. Florida Hatch-Waxman cases?
Common issues that may drive outcomes include:
- Proper venue and personal jurisdiction challenges
- Pleading sufficiency for infringement and invalidity defenses
- Claim construction timing and scope
- Expert admissibility for obviousness/enablement
- Indefiniteness standards post-Nautilus
- Inequitable conduct pleading standards
Those issues must be mapped to actual orders and rulings in this matter, which are not included.
Key Takeaways
- The provided identifier (AstraZeneca AB v. Watson Laboratories, Inc., Florida, 3:13-cv-06318) is insufficient to produce an infringement-and-procedure-specific litigation summary that includes asserted patents, FDA certifications, rulings, timeline, or settlement terms.
- A high-stakes analysis for R&D, licensing, or investment requires the complaint’s asserted patent list, the Orange Book/FDA application linkage, and the docket disposition. None of these are contained in the prompt.
FAQs
- What documents define the asserted patents and claims in AstraZeneca v. Watson 3:13-cv-06318?
- Which FDA NDA/ANDA and Paragraph IV certifications were tied to the case?
- Did AstraZeneca obtain a preliminary injunction or section 271(e)(2) ruling in 3:13-cv-06318?
- Was the litigation resolved by settlement, consent judgment, or dismissal, and on what terms?
- What Orange Book patents (by listing type and expiration) governed the dispute?
References
- Provided prompt: “AstraZeneca AB v. Watson Laboratories, Inc. - FLORIDA | 3:13-cv-06318” (no additional cited sources supplied).
